These data have given atai confidence to support an accelerated clinical development timeline NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”) today announced that it has observed encouraging interim data from the first 8-patient cohort of its Phase 2a trial, demonstrating potential pro-cognitive effects of its compound RL-007, a cholinergic, glutamatergic…


Previous articleAlgernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Next articleThe Compounds in Psychedelic Cacti